Helpful Tips on Self-Administration

With proper training, your patients can learn to administer Hizentra on their own. See below for useful tools that can assist you in their training and education.

Infusing at Home

It's very important that your patients learn proper administration techniques. CSL Behring provides a number of resources to help them every step of the way:

Hizentra Self Administration Video

Hizentra Self-Administration Video

Watch the Hizentra self-administration video to learn the step-by-step instructions on preparation, proper infusion techniques, and administration.

Step-by-Step Instructions for Self-Administering Hizentra

Step-by-Step Instructions for Self-Administering Hizentra

Use this guide when training your patients on how to properly infuse Hizentra as they walk through each step

Patient Welcome Kit

This kit provides important resources to help you start and stay on Hizentra. Your welcome kit includes:

  1. Voice2Voice Brochure
  2. Hizentra Patient Brochure
  3. Hizentra Step-by-Step Infusion Guide
  4. Hizentra Therapy Journal
  5. CSL Behring Assurance Brochure
  6. MyHizentra Infusion Manager App Brochure
  7. Prescribing Information, including Patient Product Information
  8. Additional Information

Introducing a new way to help patients maintain their therapy schedule!

The MyHizentra™ Infusion Manager app reminds patients how often they are scheduled to infuse Hizentra, and alerts patients when their next infusion is due. The app can be used by both patients and caregivers, and can be customized for each user’s schedule and preferences.

In addition, every infusion is digitally recorded by scanning the QR code of the vial(s) and providing a place for the patient to record notes. This makes it easy for patients to show you accurate infusion records during their checkups because it is all documented on their mobile phone.

SHARE Nurse Training

The objective of the SHARE (Starting Hizentra Administration with Resources and Education) program is to educate nurses and other clinicians on SCIg administration with Hizentra, as well as to provide best practices and training techniques for optimal patient care.


Important Safety Information


Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.

For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. See full prescribing information for complete boxed warning.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or components of Hizentra, such as polysorbate 80. Because it contains the stabilizer L-proline, Hizentra is contraindicated in patients with hyperprolinemia. Hizentra is also contraindicated in patients with immunoglobulin A deficiency who have antibodies against IgA and a history of hypersensitivity.

Hizentra should be administered subcutaneously only. Do not administer intravenously.

IgA-deficient patients with anti-IgA antibodies may be at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of Hizentra. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Monitor patients for aseptic meningitis syndrome (AMS), which has been reported with SCIg. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. Also monitor patients for clinical signs of hemolysis or transfusion-related acute lung injury (TRALI).

Hizentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common adverse reactions (observed in 5% or more of study subjects receiving Hizentra) were local reactions (ie, swelling, redness, heat, pain, and itching at the injection site), headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, rash, pruritus, vomiting, upper abdominal pain, migraine and pain.

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.


Immune Globulin Subcutaneous (Human), Hizentra®, is indicated as replacement therapy for patients with primary humoral immunodeficiency (PI), age 2 and older. This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Please see full prescribing information for Hizentra including boxed warning.

Professionals Using Hizentra Patient Self-Administration
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2017 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ09-12-0016(1)a 10/2015